Health
STRENGTH Trial Questions CV Benefit of High-Dose Omega-3s – Medscape
Questions about the cardiovascular benefit of omega-3 fatty acids and the high-dose eicosapentaenoic acid (EPA) product, icosapent ethyl (Vascepa, Amarin), have resurfaced with the presentation and publication of the STRENGTH trial using a combined high-dose omega-3 fatty acid product.
The STRENGTH trial showed no benefit on cardiovascular event rates of a high-dose combination of EPA and docosahexaenoic acid (DHA) in a new branded product (Epanova, AstraZeneca).
It was announced in January that…
-
Business23 hours agoIs Warren Buffett’s Berkshire Hathaway the smartest investment you can make today?
-
General23 hours agoTop chess player Magnus Carlsen forced into draw in historic game against over 134,000 people
-
Noosa News9 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
General23 hours agoTaiwan’s President Lai Ching-te calls for peace and dialogue with China while also calling for defence boosts